Pioneers in Neuroscience

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
Amyotrophic Lateral Sclerosis (ALS) at Biogen

We aspire to improve the lives of people living with and caring for those with ALS.

The future of medicine | A conversation with Alfred Sandrock

Biogen’s Executive Vice President, Research and Development, Alfred ‘Al’ Sandrock, M.D., Ph.D., on how our growing understanding of genetics coupled with the use of biomarkers and measurement tools will provide us with insights that could potentially revolutionize the field of medicine and drug development.

SOD1-ALS: Tofersen Early Access Program (EAP)
Biogen Digital Health

Biogen Digital Health aspires to transform patients’ lives and Biogen by making personalized & digital medicine in neuroscience a reality.

Healthy Climate, Healthy Lives™

Biogen marks one-year anniversary of $250 million, 20-year commitment to accelerate action on the greatest challenges of our time: climate, health and equity.

U.S. FDA approves ADUHELM™ (aducanumab-avwa) for Alzheimer’s disease

Biogen and Eisai receive FDA accelerated approval for a new therapy targeting amyloid beta plaque.

10/20/21 7:00 AM EDT
Biogen Reports Third Quarter 2021 Results
View all news
Biogen updates delivered to your inbox
Diversity, Equity and Inclusion

Biogen is committed to the power of diversity – in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us.

Where Science Meets Humanity

Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen.

Follow us on social media